Yanuki
News / Clinical Trials
Spero Therapeutics and GSK have announced positive results from their Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs). The trial was stopped early due to ef...
Complicated urinary tract infections (cUTIs) pose a significant healthcare burden, often requiring hospitalization and intravenous antibiotic treatment. The current standard of care includes carbapenem antibiotics, which are highly effective but only available for IV administration. Spero Therapeutics and GSK's development of tebipenem HBr aims to address this limitation by providing an oral carbapenem option.
The PIVOT-PO trial was a global, randomized, double-blind study that enrolled 1,690 patients with cUTIs, including pyelonephritis. Patients were randomized to receive either oral tebipenem HBr or intravenous imipenem-cilastatin. The primary efficacy endpoint was the overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit.
The trial met its primary endpoint, demonstrating that tebipenem HBr was non-inferior to intravenous imipenem-cilastatin. The IDMC's recommendation to stop the trial early further underscores the strength of the efficacy data. The safety profile of tebipenem HBr was consistent with previous studies, with diarrhea and headache being the most commonly reported adverse events.
The development of tebipenem HBr is supported by federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA). This funding highlights the importance of developing new treatments for multi-drug resistant bacterial infections.
**Actionable takeaways:** - Patients with cUTIs may soon have access to an oral carbapenem antibiotic, reducing the need for hospitalization and IV treatments. - Healthcare providers should stay informed about the potential approval and availability of tebipenem HBr to optimize treatment strategies for cUTIs. - The successful development of tebipenem HBr demonstrates the importance of investing in research and development of new antibiotics to combat multi-drug resistant infections.
The trial met its primary endpoint early, demonstrating non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in treating complicated urinary tract infections (cUTIs).
GSK plans to submit the FDA filing in the second half of 2025, which will include the PIVOT-PO trial data.
The drug addresses an estimated 2.9 million annual cUTI cases in the US, with current treatments contributing to over $6 billion in yearly healthcare costs.
The most commonly reported adverse events in the trial were diarrhea and headache.
If approved, tebipenem HBr would be the first oral carbapenem antibiotic for US patients with cUTIs, potentially reducing the need for hospital-based intravenous treatment.
Do you think this new oral treatment will significantly impact the management of complicated UTIs? Share this article with others who need to stay ahead of this trend!
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.
